mRNA-1073
Phase 2Completed 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SARS-CoV-2, Influenza
Conditions
SARS-CoV-2, Influenza
Trial Timeline
May 13, 2022 → Dec 29, 2022
NCT ID
NCT05375838About mRNA-1073
mRNA-1073 is a phase 2 stage product being developed by Moderna for SARS-CoV-2, Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT05375838. Target conditions include SARS-CoV-2, Influenza.
What happened to similar drugs?
4 of 20 similar drugs in SARS-CoV-2, Influenza were approved
Approved (4) Terminated (1) Active (16)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05375838 | Phase 2 | Completed |
Competing Products
20 competing products in SARS-CoV-2, Influenza
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1283 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1273.214 | Moderna | Phase 2 | 0 |
| SPIKEVAX | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| SPIKEVAX Bivalent | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 2 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273.211 | Moderna | Phase 3 | 0 |
| SPIKEVAX (mRNA-1273) | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 2 | 0 |